Inventor · disambiguated record
Jaroslaw Kalisiak
Also filed as: KALISIAK JAROSLAW
34 granted patents·5 pending applications·169 citations·filing 2015–2024
97Inventor score
Top patents by PatentIndex Score
39 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0298US9834545B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2016·Granted Dec 5, 2017·26 cites·33 claims
- 0397US9809581B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2016·Granted Nov 7, 2017·23 cites·29 claims
- 0496US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0595US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0695US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0795US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 0894US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0994US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 1094US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 1194US10370363B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2017·Granted Aug 6, 2019·6 cites·13 claims
- 1294US10336736B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2017·Granted Jul 2, 2019·6 cites·24 claims
- 1394US9745268B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Aug 29, 2017·11 cites·31 claims
- 1493US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 1593US10266492B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Apr 23, 2019·8 cites·10 claims
- 1692US12145901B1Process for preparing tetralin compoundsARCUS BIOSCIENCES INC·Filed 2022·Granted Nov 19, 2024·2 cites·25 claims
- 1791US10988464B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2019·Granted Apr 27, 2021·3 cites·16 claims
- 1890US11040960B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2019·Granted Jun 22, 2021·3 cites·14 claims
- 1989US10532982B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jan 14, 2020·4 cites·1 claims
- 2086US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 2186US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 2285US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 2383US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2482US2025214930A1Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2580US9795599B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2016·Granted Oct 24, 2017·2 cites·24 claims
- 2679US11845729B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2022·Granted Dec 19, 2023·0 cites·10 claims
- 2779US11267845B2Inhibitors of CD73-mediated immunosuppressionARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 8, 2022·1 cites·32 claims
- 2878US10117865B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2017·Granted Nov 6, 2018·1 cites·6 claims
- 2974US12054484B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2021·Granted Aug 6, 2024·0 cites·8 claims
- 3074US11945805B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2021·Granted Apr 2, 2024·0 cites·9 claims
- 3173US11820759B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2021·Granted Nov 21, 2023·0 cites·8 claims
- 3273US10786494B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2018·Granted Sep 29, 2020·0 cites·5 claims
- 3372US2020354320A1PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTSCHEMOCENTRYX INC·Filed 2019·Application pending·0 cites
- 3470US2020121688A1Substituted tetrahydropyrans as ccr2 modulatorsCHEMOCENTRYX INC·Filed 2019·Application pending·0 cites
- 3569US2025230173A1Salt forms of an axl inhibitorARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3652US10570088B2Blood brain barrier-penetrating oximes for cholinesterase reactivationHUMAN BIOMOLECULAR RES FOUNDATION·Filed 2017·Granted Feb 25, 2020·0 cites·14 claims
- 3750US12226425B2Inhibitors of ARG1 and/or ARG2ARCUS BIOSCIENCES INC·Filed 2019·Granted Feb 18, 2025·0 cites·11 claims
- 3850US12054500B2Arginase inhibitorsARCUS BIOSCIENCES INC·Filed 2019·Granted Aug 6, 2024·0 cites·13 claims
- 3949US12433836B2Parenterally administered immune enhancing drugsARCUS BIOSCIENCES INC·Filed 2019·Granted Oct 7, 2025·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when Jaroslaw Kalisiak files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →